Mayr, Christian <br/><br/>
The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.  [electronic resource] 

 -  Oncotarget  Jan 2016 
 - 745-58 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.6378  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Biliary Tract Neoplasms--genetics<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Cisplatin--pharmacology<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>Flow Cytometry<br/>G1 Phase Cell Cycle Checkpoints--drug effects<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Heterocyclic Compounds, 2-Ring--pharmacology<br/>Humans<br/>Immunohistochemistry<br/>Neoplastic Stem Cells--drug effects<br/>Polycomb Repressive Complex 1--antagonists & inhibitors<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Thiazoles--pharmacology